Introduction
============

Bladder cancer (BC) is the leading cause of death among urological cancers, with an estimated 81,190 new cancer cases and 17,240 deaths in the US in 2018.[@b1-ott-11-3075]

Approximately 70% of BC is non-muscle-invasive bladder cancer (NMIBC) at first diagnosis; however, roughly 20% of NMIBC will progress to muscle-invasive BC (MIBC).[@b2-ott-11-3075] Owing to the aggressive metastasis and delayed diagnosis, the prognosis of MIBC is still poor.[@b3-ott-11-3075] Although some conventional methods such as surgery and cytotoxic chemotherapy can be applied, the recurrence rate can be up to 70% within 2 years, which makes the treatment of BC unsatisfactory.[@b4-ott-11-3075] The thorough understanding of molecular mechanism and biological markers can help in the early detection, risk stratification, appropriate therapeutic intervention and prognosis in patients with BC.

MicroRNA (miRNA) is a group of single-stranded short RNA molecules (generally 21 nucleotides) that take part in the posttranscriptional gene regulation.[@b5-ott-11-3075] Emerging evidence reveals that miRNAs are involved in the various stages such as tumor initiation, proliferation, migration and invasion.[@b6-ott-11-3075],[@b7-ott-11-3075] MiRNAs can also functionally act as oncogene or tumor suppressors.[@b8-ott-11-3075] The detection technique of miRNA in serum, urine and biopsy specimen is available; therefore, miRNA is an attractive source of noninvasive biomarkers.[@b9-ott-11-3075] The quantitative reverse transcription polymerase chain reaction (qRT-PCR), small RNA sequencing and microarray are widely applied in BC researches in the past decade. In addition, the utility of miRNA as diagnosis or prognosis markers has generated a great interest. However, the results of different studies are inconclusive due to the heterogeneous ethnicity, sample size, different sample types and less clinical parameters.

To the best of our knowledge, few studies have reported the miRNAs and miRNA--mRNA regulatory networks by integrating multiple microarray datasets. Therefore, a comprehensive analysis was administrated in this study to further elucidate the key miRNAs, regulatory pathways and clinical significance in BC.

Materials and methods
=====================

Microarray data
---------------

Three miRNA expression profiles (GSE36121, GSE39093 and GSE68594) and three gene expression profiles (GSE27448, GSE40355 and GSE52519) were obtained by the search of the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>). The profiles based on BC cell lines or xenograft models were excluded; thus, only BC patients and healthy controls were included in this study. [Table S1](#SD2-ott-11-3075){ref-type="supplementary-material"} lists the detailed characteristics of the profiles. Every included dataset from the abovementioned profiles contains at least 10 BC samples and normal bladder tissues ([Table 1](#t1-ott-11-3075){ref-type="table"}).

Data processing
---------------

We performed the comparison between the two groups of samples (BC versus normal prostate tissues) in each GEO dataset to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs). The comparison was launched by a Limma R package based on online program, GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>). The adjusted *P*-value from the Benjamini--Hochberg method can correct the false-positive results, and the "adjusted *P*-value\<0.05" and "\|log FC\|\>1" parameters were chosen as primary cutoff criteria to test the results. Among the DEMs from the four datasets, only those involved in two or more datasets could be considered the statistically significant DEMs.

Identification of miRNA targets
-------------------------------

The MiRWalk 2.0 database provides a large collection of predicted and experimentally verified information about the binding targets of miRNAs.[@b10-ott-11-3075] We downloaded the data of the significant DEMs and their target mRNAs from the MiRwalk 2.0 retrieval system, which was based on experimental literature reports. Despite the fact that validated target genes were from various disease models, the expression of those genes in BC might not be in consistent with other diseases. Hence, it is important to select the genes from the intersection between the significant DEM--mRNA intersection data and the DEGs from the three GEO datasets. These genes were finally defined as the significant DEGs.

Functional enrichment analysis
------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID) is an online platform that offers the functional annotation and analysis of enormous quantity of genes derived from various genomic resources.[@b11-ott-11-3075] We used the DAVID database to conduct gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on significant DEGs. The species was limited to homo sapiens, and the "adjusted *P*-value (from the Benjamini--Hochberg method) \<0.05" was considered statistically significant.

Interaction and regulatory network establishment
------------------------------------------------

The protein--protein interaction (PPI) was visualized, and its network was constructed by the use of Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), whose database can collect and predict the interaction information from genomic context predictions, high-throughput laboratory experiments, co-expression, automated text mining and previous knowledge in databases.[@b12-ott-11-3075] The data annotated from high-throughput laboratory experiments and previous knowledge in databases were imposed to access the more objective and reliable results, and the minimum interaction value was set at medium confidence (0.400).

The Targetscan (<http://www.targetscan.org/>) is a famous miRNA prediction database by searching for the presence of conserved 8mer, 7mer and 6mer sites that match the seed region of each miRNA. The miRanda algorithm from the "[microRNA.org-Targets](http://microRNA.org-Targets) and Expression" is freely available and can be applied to the whole genome sequences using identified miRNA sequences.[@b13-ott-11-3075] The two programs mentioned earlier were used to predict target mRNAs of the significant DEMs. We note that two miRNAs shared a common target mRNA; they might exist in a similar regulatory pathway. The miRNA--mRNA regulatory network was visualized by using Cytoscape 3.6.0.[@b14-ott-11-3075]

Validation and survival analysis
--------------------------------

The Cancer Genome Atlas (TCGA) database provides abundant clinical information from huge sample size. Therefore, the dataset "TCGA-BLCA (<https://portal.gdc.cancer.gov/>)" was used to find if the significant DEMs were in correlation with survival outcome. The dataset contains 412 patients who were diagnosed as having BC in the period of 1999--2013. Among them, 304 patients are male, while 108 are female. As for the race, 327 BC patients are white, 44 are Asian and 23 are black or African-American, and 23 were not reported. Among the 404 clinical outcome events available, 227 patients were living and 177 were dead when the follow-up ended. We examined the significant DEMs' expression, relationship with BC stages and survival. The "independent two-sample Student's *t*-test" was applied to check the expression level, while the chi-square test was used on different stages. The Kaplan--Meier plots were constructed using Oncolnc.[@b15-ott-11-3075] The "*P*-value\<0.05" was considered statistically significant.

Results
=======

DEG/DEM identification
----------------------

After compared with normal bladder tissues, the results of GEO2R analysis showed that there were totally 159 DEMs ([Figure 1A](#f1-ott-11-3075){ref-type="fig"}), 4,013 upregulated DEGs ([Figure 1B](#f1-ott-11-3075){ref-type="fig"}) and 4236 downregulated DEGs ([Figure 1C](#f1-ott-11-3075){ref-type="fig"}). Among them, 18 DEMs appeared in the results of two datasets at least, so they could be identified as significant DEMs. Interestingly, miR-145 was the only DEM in all three datasets simultaneously. The following DEMs were found in every two different datasets: miR-429, miR-487b, miR-494, miR-222, miR-335, miR-202, miR-212, miR-200a, miR-125b, miR-210, miR-214, miR-182, miR-99a, miR-100 and miR-138. Subsequently, we further compared clinical stages T2--T4 versus Ta--T1 and high histological grade versus low grade to identify DEMs which might be related to aggressive BC. Interestingly, only miR-601 and hsa-let-7c appeared in two dataset intersections ([Figure S1](#SD1-ott-11-3075){ref-type="supplementary-material"}).

Using the MiRWalk 2.0-validated-target miRNA-gene retrieval system, we got 9,053 candidate genes of the 18 significant DEMs. The intersection number of these candidate genes and the upregulated DEGs which appeared in two or more datasets was 121, while the intersection number of these candidate genes and the downregulated DEGs which appeared in two or more datasets was 199. Therefore, the 121 upregulated and the 199 downregulated genes were identified as the final sets of significant DEGs.

GO and pathway enrichment
-------------------------

The GO ontology contains three terms: cellular component, molecular function and biological process. The three terms mentioned earlier were used to identify the key biological functions. The results demonstrated that the most significant GO terms for upregulated significant DEGs were "nucleoplasm," "protein binding" and "cell division." Whereas for the downregulated significant DEGs, the terms "costamere," "heparin binding" and "cell--matrix adhesion" turned to be important ([Table 2](#t2-ott-11-3075){ref-type="table"}).

Furthermore, the KEGG pathway analysis indicated that "cell cycle," "MAPK signaling pathway," "pathways in cancer" and "proteoglycans in cancer" pathways played an essential role in BC pathogenesis ([Table 2](#t2-ott-11-3075){ref-type="table"}).

PPI network
-----------

The PPI networks were established separately by the significant upregulated DEGs ([Figure 2A](#f2-ott-11-3075){ref-type="fig"}) and significant downregulated DEGs ([Figure 2B](#f2-ott-11-3075){ref-type="fig"}). As for the former, 64 nodes and 172 edges in total constituted the PPI network. As for the latter, the network was composed of 73 nodes and 80 edges.

In a single PPI network, the more edges a gene has, the more important role it plays (like a seed). We utilized the parameter "degree" to calculate edge counts of every single gene in a PPI network. The top 5% degree genes are listed in [Table 3](#t3-ott-11-3075){ref-type="table"}, which were assessed as the hub genes.

MiRNA--mRNA regulatory network
------------------------------

As illustrated in [Figure 3](#f3-ott-11-3075){ref-type="fig"}, the target genes were predicted using miRanda and miRTarbase, among which two or more miRNAs might target the same mRNA. For instance, both miR-92a and miR-145 had the interactions with cyclin-dependent kinase 4 (CDK4). There were 12 mRNA nodes that might interact with at least two miRNAs.

Validation and Kaplan--Meier curves
-----------------------------------

After comparing the expression level of miRNAs in the TCGA dataset, we found that 13 among the 18 significant DEMs were according to the results in GEO databases. In contrast, the expression of miR-92, miR-494, miR-429, miR-202 and miR-212 was not significantly different between BC samples and normal control bladder tissues. The relationship between miRNAs and the clinical TNM stages was also tested in the TCGA dataset by using chi-square analysis. The results of the significant DEMs are summarized in [Table 4](#t4-ott-11-3075){ref-type="table"}.

We subsequently drew Kaplan--Meier plots ([Figure 4](#f4-ott-11-3075){ref-type="fig"}) based on the TCGA survival data. The plots indicated that eight significant DEMs, such as miR-99a, miR-100, miR-125b, miR-138, miR-145, miR-200, miR-214 and miR-487b, were found to be related to overall survival (OS) in BC patients. The higher expression of the abovementioned miRNAs meant the poor OS in patients with BC except miR-138 and miR-200a.

Discussion
==========

In the current study, 18 significant DEMs, 121 upregulated DEGs and 199 downregulated DEGs were identified after integrating and screening multiple datasets. The results of functional enrichment analysis indicated that the significant DEGs in BC were related to classical cancer pathways such as cell cycle and MAPK signaling pathways. The key DEGs such as CDK1, CCNB1, VCL and PRKCA were defined as the hub genes in the PPI networks. Significantly, most of the DEMs were correlated with tumor stages and OS in the TCGA datasets, which meant that the miRNAs have high clinical application value in the prognosis of BC.

BC shares many acknowledged pathways with other human cancers such as p53 and MAPK pathways. With the growing in-depth studies of BC, people have found a great deal of key molecules at gene, transcription regulation and protein interaction level. In these complicated processes, miRNAs nearly take part in all key cellular pathways because one miRNA can interact with many mRNAs and one mRNA can also interact with a lot of miRNAs. Intriguingly, miR-145 was the only one significant DEM that was identified in all three different datasets. We assumed that the source of heterogeneity might be ethnic and sample size. The expression level of miR-145 was higher in BC tissue and cell line than normal control.[@b16-ott-11-3075],[@b17-ott-11-3075] Minami et al[@b18-ott-11-3075] reported that miR-145 could negatively regulate Warburg effect by silencing KLF4 and PTBP1. Long noncoding RNA (lncRNA) can also interact with miRNA in cancer pathways. LncRNA UCA-1 can promote BC cell migration and invasion by hsa-miR-145-ZEB1/2-FSCN1 pathway.[@b19-ott-11-3075] miR-21 regulates cell proliferation and migration by targeting PTEN and p53 in BC.[@b20-ott-11-3075] miR-202,[@b21-ott-11-3075] miR-212,[@b22-ott-11-3075] miR-222,[@b23-ott-11-3075] miR-429,[@b24-ott-11-3075] miR-200,[@b25-ott-11-3075] miR-210,[@b26-ott-11-3075] miR-214,[@b27-ott-11-3075] miR-182,[@b28-ott-11-3075] miR-99a,[@b29-ott-11-3075] miR-100[@b30-ott-11-3075] and miR-138[@b31-ott-11-3075] were reported in BC studies, which were mostly dependent on cell lines. The studies on miRNA relationship with BC survival were insufficient. Urine is an ideal source of biomarkers due to the easily acquired and noninvasive property.[@b32-ott-11-3075] Recently, it was reported that inflammation could drive tumor growth and progression.[@b33-ott-11-3075],[@b34-ott-11-3075] Mearini et al[@b34-ott-11-3075] reported that although the expression of miR-145 in urine was higher in BC than in inflammation, and even higher in the high histological grade or high clinical stages, the results were not statistically significant. The expression of miR-145 was significantly higher in BC tissues in our results. It is assumed that the difference may be owing to low secretion amount or degradation. Therefore, we need the microarray studies concerning miRNAs in serum or urine as biomarkers in BC based on large sample sizes in the future.

Our studies may also provide hints for new target genes and pathways in the basic experiments of BC. Except for the previously reported miRNAs, there are also some miRNAs not reported in BC such as miR-335, miR-125b, miR-494 and miR-487b. We found that the higher miR-125b and miR487b expression suggested the poor survival based on 404 patients in TCGA. The mechanisms and in-depth pathways of these miRNAs should be investigated by experiments in the future.

By constructing the PPI network, we can recognize the key genes which miRNAs may interact with. Since the genes were filtered by the 18 significant DEMs' potential targets, there were still 121 upregulated and 199 downregulated genes. Therefore, when it comes to all the 159 DEMs, the enormous and complicated miRNA--mRNA regulatory network can be imaginable. The hub genes of a network are always important like "seeds," which connect the different signal pathways. In the current study, we identified several hub genes. Among the downregulated DEGs, the vinculin and protein kinase C alpha were identified. The vinculin was reported as a potential prognostic biomarker and the target for prostate cancer cell migration.[@b35-ott-11-3075] Whereas in the upregulated DEGs, the hub gene *CDK1* and cyclin B1 are associated with cell cycle and proliferation.[@b36-ott-11-3075] Within the miRNA--mRNA network, we constructed that the key mRNAs such as CDK6 and CDK4 were cell-cycle-related modulators, while BCL2L11 was related to autophagy and apoptosis.[@b37-ott-11-3075] In conclusion, the miRNA regulatory network may provide potential targets for new drug development and treatment.

Although this study first investigated miRNAs' regulatory role in BC by integrating multiple microarray profiles, some limitations should be clarified. First, the gender, races of BC patients, tumor stages or grades were different in the included datasets, which may cause heterogeneity. Second, the source of microarray is only tissue. Body fluids such as serum, urine, may contain circulating miRNAs, which are noninvasive to be applied in the clinical practice. Third, although our results were validated in TCGA dataset, the integrating analysis results were not validated by the experiments such as qRT-PCR and functional experiments in vitro. Further studies are required to validate our results by the experiments on larger sample sizes and clinical follow-up in different ethnics.

Conclusion
==========

In this study, we found a total of 18 DEMs which may play key roles in the pathways such as cell cycle and MAPK pathway in the regulatory networks of BC. The higher expression of miR-99a, miR-100, miR-125b, miR-145, miR-214 and miR-487b or the lower expression of miR-138 and miR-200a can indicate poor survival in the prognosis of BC. Further experimental studies are required to test our results.

Supplementary materials
=======================

###### 

Venn diagram of DEMs (**A**: Ta--T1 vs T2--T4; **B**: G3 vs G1) in different datasets.

**Notes:** (**A**) GSE36121: hsa-miR-135b, hsa-miR-508, hsa-miR-7, hsa-miR-21, hsa-miR-615, hsa-miR-124, hsa-miR-106b, hsa-miR-98, hsa-miR-132, hsa-miR-30e, hsa-miR-130a, hsa-miR-193a, hsa-miR-582, hsa-miR-151, hsa-let-7c. GSE39093: hsa-mir-1308, hsa-mir-192, hsa-mir-574, hsa-mir-720, hsa-mir-92b. GSE68594: hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7f, hsa-let-7i, hsa-mir-155, hsa-mir-196, hsa-mir-429, hsa-mir-579. (**B**) GSE36121: hsa-miR-1224-5p, hsa-miR-1225-5p, hsa-miR-1228, hsa-miR-125a-3p, hsa-miR-134, hsa-miR-135a, hsa-miR-135b, hsa-miR-136, hsa-miR-146a, hsa-miR-150, hsa-miR-188-5p, hsa-miR-192, hsa-miR-193a-3p, hsa-miR-194, hsa-miR-197, hsa-miR-21, hsa-miR-224, hsa-miR-31, hsa-miR-345, hsa-miR-362-5p, hsa-miR-363, hsa-miR-371-5p, hsa-miR-423-5p, hsa-miR-508-5p, hsa-miR-518c, hsa-miR-532-5p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-582-5p, hsa-miR-598, hsa-miR-601, hsa-miR-622, hsa-miR-629, hsa-miR-663, hsa-miR-671-5p, hsa-miR-7, hsa-miR-801, hsa-miR-940. GSE68594: hsa-let-7d, hsa-let-7f, hsa-let-7i, hsa-mir-122a, hsa-mir-184, hsa-mir-196a1, hsa-mir-196a2, hsa-mir-203, hsa-mir-206, hsa-mir-223, hsa-mir-34a, hsa-mir-595, hsa-mir-601, hsa-mir-611-P.

**Abbreviations:** DEMs, differentially expressed miRNAs; miRNAs, microRNAs.

###### 

Detailed information of patients in each included GEO datasets

  Accession/ID   Ethnic group   Number of males/females   Range of age (years)   Number of BC tissues with different histological grades   Number of NMIBC/MIBC tissues
  -------------- -------------- ------------------------- ---------------------- --------------------------------------------------------- ------------------------------
  GSE36121       Caucasian      22/2                      47--80                 G1: 3, G2: 6, G3: 7                                       NMIBC: 13, MIBC: 3
  GSE39093       Chinese Han    10/0                      55--73                 NR                                                        NMIBC: 5, MIBC: 5
  GSE68594       Caucasian      39/5                      36--86                 G1: 4, G2: 14, G3: 15                                     NMIBC: 18, MIBC: 15
  GSE27448       Caucasian      15/0                      44--86                 G1: 0, G2: 3, G3: 7                                       NMIBC: 6, MIBC: 4
  GSE40355       NR             20/2                      47--80                 G1: 3, G2: 6, G3: 7                                       NMIBC: 13, MIBC: 3
  GSE52519       NR             11/1                      43--77                 G1: 0, G2: 4, G3: 5                                       NMIBC: 3, MIBC: 6

**Abbreviations:** BC, bladder cancer; GEO, Gene Expression Omnibus; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle-invasive bladder cancer; NR, not reported.
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![Venn diagram of DEM/DEG selection in different datasets.\
**Notes:** (**A**) DEMs; (**B**) upregulated DEGs; (**C**) downregulated DEGs.\
**Abbreviations:** DEGs, differentially expressed genes; DEM, differentially expressed miRNA; miRNAs, microRNAs.](ott-11-3075Fig1){#f1-ott-11-3075}

![PPI network of DEGs.\
**Notes:** (**A**) Upregulated DEGs; (**B**) downregulated DEGs.\
**Abbreviations:** DEGs, differentially expressed genes; PPI, protein--protein interaction.](ott-11-3075Fig2){#f2-ott-11-3075}

![The miRNA--mRNA regulatory network.\
**Note:** Round nodes, miRNA; square nodes, mRNA; green line, from Targetscan database; blue line, from miRanda prediction.\
**Abbreviation:** miRNA, microRNA.](ott-11-3075Fig3){#f3-ott-11-3075}

###### 

The Kaplan--Meier plots of patients from TCGA dataset.

**Notes:** Survival plots of the bladder cancer patients with high and low expression of miR-145-3p (**A**), miR-126-5p (**B**), miR-99a-5p (**C**), miR-100-5p (**D**), miR-214-5p (**E**), miR-487b-3p (**F**), miR-200a-3p (**G**) and miR-138-5p (**H**).

**Abbreviation:** TCGA, The Cancer Genome Atlas.
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###### 

Characteristics of the microarray datasets from GEO database

  Accession/ID   PMID              Platform   Number of BC tissues          Number of normal bladder tissues (control)   Gene/miRNA
  -------------- ----------------- ---------- ----------------------------- -------------------------------------------- ------------
  GSE36121       22745731          GPL8227    n=16 (Ta--T1=13, T2--T4=3)    n=8                                          miRNA
  GSE39093       23270926          GPL8786    n=10 (Ta--T1=5, T2--T4=5)     n=10                                         miRNA
  GSE68594       26943042          GPL20120   n=33 (Ta--T1=18, T2--T4=15)   n=17                                         miRNA
  GSE27448       [21483740]{.ul}   GPL2895    n=10 (Ta--T1=6, T2--T4=4)     n=5                                          Gene
  GSE40355       --                GPL13497   n=16 (Ta--T1=13, T2--T4=3)    n=8                                          Gene
  GSE52519       --                GPL6884    n=9 (Ta--T1=3, T2--T4=6)      n=3                                          Gene

**Abbreviations:** BC, bladder cancer; GEO, Gene Expression Omnibus; miRNA, microRNA; PMID, PubMed ID.

###### 

Results of significant GO biological processes and the KEGG pathway analysis

  Category             Description                        Gene counts   Adjusted *P*-value
  -------------------- ---------------------------------- ------------- --------------------
  Upregulated gene                                                      
   GO:0005654, CC      Nucleoplasm                        49            4.40E-09
   GO:0005634, CC      Nucleus                            65            2.20E-06
   GO:0000777, CC      Condensed chromosome kinetochore   7             8.70E-04
   GO:0005819, CC      Spindle                            8             9.30E-04
   GO:0030496, CC      Midbody                            8             1.10E-03
   GO:0005515, MF      Protein binding                    89            1.40E-06
   GO:0003682, MF      Chromatin binding                  16            6.00E-06
   GO:0005524, MF      ATP binding                        26            1.10E-03
   GO:0051301, BP      Cell division                      19            1.40E-08
   GO:0007067, BP      Mitotic nuclear division           14            4.70E-06
   GO:0007062, BP      Sister chromatid cohesion          9             1.30E-04
   GO:0016925, BP      Protein sumoylation                8             3.00E-03
   GO:0007052, BP      Mitotic spindle organization       5             8.40E-03
   KEGG: hsa04110      Cell cycle                         12            6.20E-08
  Downregulated gene                                                    
   GO:0043034, CC      Costamere                          7             7.10E-06
   GO:0043034, CC      Focal adhesion                     18            1.00E-04
   GO:0015629, CC      Actin cytoskeleton                 12            1.60E-03
   GO:0005576, CC      Extracellular region               35            3.90E-03
   GO:0070062, CC      Extracellular exosome              51            4.30E-03
   GO:0008201, MF      Heparin binding                    11            3.20E-03
   GO:0003779, MF      Actin binding                      13            8.50E-03
   GO:0007160, BP      Cell--matrix adhesion              8             4.30E-02
   KEGG: hsa04110      MAPK signaling pathway             14            1.80E-03
   KEGG: hsa05200      Pathways in cancer                 15            2.10E-02
   KEGG: hsa05205      Proteoglycans in cancer            10            3.80E-02

**Abbreviations:** BP, biological process; CC, cellular component; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.

###### 

The top 5% hub genes in the PPI networks

  Ensembl gene ID      Gene symbol   Full gene name                                          Degree
  -------------------- ------------- ------------------------------------------------------- --------
  Upregulated gene                                                                           
   ENSG00000170312     *CDK1*        Cyclin-dependent kinase 1                               25
   ENSG00000134057     *CCNB1*       Cyclin B1                                               21
   ENSG00000072501     *SMC1A*       Structural maintenance of chromosomes 1A                16
   ENSG00000117399     *CDC20*       Cell division cycle 20                                  14
  Downregulated gene                                                                         
   ENSG00000035403     *VCL*         Vinculin                                                8
   ENSG00000154229     *PRKCA*       Protein kinase C alpha                                  8
   ENSG00000170345     *FOS*         Fos proto-oncogene, AP-1 transcription factor subunit   7
   ENSG00000168610     *STAT3*       Signal transducer and activator of transcription 3      5

**Abbreviation:** PPI, protein--protein interaction.

###### 

Results of the significant DEM expression validation and the relationship with bladder cancer clinical stages in TCGA dataset

  miRNA ID          Higher expression   *P*-value (*t*-test)[\*](#tfn4-ott-11-3075){ref-type="table-fn"}   Pathological stages         *P*-value (chi-square)
  ----------------- ------------------- ------------------------------------------------------------------ --------------------------- ----------------------------
  hsa-miR-145-3p    Normal              1.73e-06                                                           Pathological T/N/M status   4.76e-04/8.90e-05/9.62e-04
  hsa-miR-21-3p     Tumor               1.79e-04                                                           Pathological M status       7.27e-03
  hsa-miR-487b-3p   Normal              1.92e-11                                                           Pathological T status       3.87e-03
  hsa-miR-494-3p    --                  --                                                                 Pathological T status       2.65e-02
  hsa-miR-222-3p    Tumor               4.10e-02                                                           Pathological M status       5.54e-03
  hsa-miR-335-3p    Tumor               1.64e-06                                                           --                          --
  hsa-miR-212-3p    --                  --                                                                 Pathological T/M status     2.21e-03/1.60e-02
  hsa-miR-200a-3p   Tumor               8.14e-05                                                           Pathological T/M status     1.41e-03/7.23e-06
  hsa-miR-210-3p    Tumor               3.43e-08                                                           Pathological T/N status     3.01e-02/4.59e-03
  hsa-miR-214-3p    --                  --                                                                 Pathological T/M status     1.84e-07/1.74e-03
  hsa-miR-182-3p    Tumor               1.59e-02                                                           Pathological M status       2.34e-06
  hsa-miR-100-3p    --                  --                                                                 Pathological T status       4.15e-02
  hsa-miR-145-5p    Normal              1.33e-04                                                           Pathological T/N/M status   7.14e-03/1.79e-03/7.26e-05
  hsa-miR-21-5p     Tumor               2.42e-06                                                           Pathological M status       5.83e-06
  hsa-miR-222-5p    Tumor               1.43e-02                                                           --                          --
  hsa-miR-335-5p    Tumor               5.22e-05                                                           Pathological M status       1.85e-02
  hsa-miR-200a-5p   Tumor               7.68e-05                                                           --                          --
  hsa-miR-125b-5p   Normal              4.25e-02                                                           Pathological T/N/M status   3.26e-05/8.07e-04/5.08e-06
  hsa-miR-214-5p    Tumor               9.80e-03                                                           Pathological T/N/M status   5.29e-09/2.15e-03/5.31e-07
  hsa-miR-182-5p    Tumor               1.03e-06                                                           Pathological M status       6.18e-05
  hsa-miR-99a-5p    Normal              1.94e-02                                                           Pathological T/N/M status   1.63e-07/1.10e-03/4.17e-04
  hsa-miR-100-5p    Normal              7.01e-04                                                           Pathological T/N/M status   6.86e-04/6.83e-04/5.99e-07
  hsa-miR-138-5p    Tumor               9.07e-03                                                           Pathological T/N status     1.24e-02/3.73e-02

**Note:**

Independent two-sample Student's *t*-test.

**Abbreviations:** DEMs, differentially expressed miRNAs; miRNAs, microRNAs; TCGA, The Cancer Genome Atlas.
